Psilocybin vs. cannabis: comparing two very different substances people often conflate
234 replies · General
Legalization discussions often group these together and I find this frustrating. They are fundamentally different substances with different risks, different mechanisms, and different policy implications. Can we have a serious comparison?
Key mechanistic difference: cannabis primarily acts via endocannabinoid CB1/CB2 receptors. Psilocybin primarily acts via serotonergic 5-HT2A receptors. These are completely different receptor systems with different brain distributions. The experiential differences — cannabis's sedation/appetite effects vs. psilocybin's introspective/mystical effects — reflect this mechanistic difference directly.
Addiction profile: cannabis can produce dependence in regular users (roughly 9% of users). Psilocybin: no documented addiction in human populations; actually used in treating addictions to other substances. The tolerance mechanism for psilocybin (rapid receptor downregulation) makes compulsive use almost impossible.
Policy lesson: cannabis's legal status has been shaped by 50+ years of medicalization politics. Psilocybin's trajectory is being shaped much more by clinical trial data. The different evidentiary bases are producing different regulatory frameworks, and conflating the two in policy discussions generates confusion about the relevant evidence.
231 more replies — forum posting coming soon.